[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:triple-negative-breast-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":225,"states":230},"Triple-Negative Breast Carcinoma",35,29,[8,16,23,29,35,41,48,54,60,67,73,79,85,92,98,104,109,115,121,127,133,139,145,151,157,163,169,175,181,187,194,200,206,213,219],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06841354","A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011\u002FTroFuse-011)",[12],"Phase 3","RECRUITING","2026-08-26T02:18:59.761994Z","2026-06-16T05:54:07.924230Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07017673","Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer",[20],"Phase 2","2026-08-26T02:17:11.311767Z","2026-05-05T02:43:29.360234Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05491226","Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation",[20],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:29.329083Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04683679","A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive\u002FHer2 Negative Breast Cancer",[20],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:28.824547Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07016399","Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC",[20],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:28.671324Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT06926868","A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)",[45],"Phase 2\u002FPhase 3","2026-08-26T02:16:57.705506Z","2026-05-05T02:43:28.347122Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06393374","Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)",[12],"2026-08-26T02:15:00.557154Z","2026-05-05T02:43:28.181556Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06103864","A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer",[12],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.810861Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT05422794","Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer",[64],"Phase 1","2026-08-26T02:16:16.995720Z","2026-05-05T02:43:27.628438Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06492759","High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer",[20],"2026-08-26T02:17:57.117858Z","2026-05-05T02:35:31.915366Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06324240","Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer",[64],"2026-08-26T02:15:28.524219Z","2026-05-05T02:35:31.741776Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05741164","Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer",[20],"2026-08-26T02:17:05.997056Z","2026-05-05T02:35:31.616333Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":90,"content_modified":91},"NCT04300556","A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types",[89],"Phase 1\u002FPhase 2","2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.794460Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT05660083","Alpelisib\u002FiNOS Inhibitor\u002FNab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)",[20],"2026-08-26T02:15:49.658025Z","2026-05-05T02:43:28.532207Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT05768932","BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia",[64],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:26.985595Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":52,"content_modified":108},"NCT05720117","A Study of PYX-201 in Advanced Solid Tumors",[64],"2026-05-05T02:35:31.901523Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07197671","Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer",[64],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.735881Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05867251","Study of AVZO-021 in Patients With Advanced Solid Tumors",[89],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:29.354579Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT05101070","S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors",[89],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:28.621667Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07517198","Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors",[64],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:27.930022Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT05674825","Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses",[89],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.840688Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT04787042","Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067",[89],"2026-08-26T02:19:08.862440Z","2026-05-05T02:43:27.747454Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT06425926","Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors",[89],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:27.481608Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05581004","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",[64],"2026-08-03T03:43:00.111924Z","2026-05-05T02:43:27.397730Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT07312903","DPTX3186 in Wnt Pathway Activated Solid Tumors",[64],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:27.279334Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06657222","First in Human Study of TUB-030 in Patients With Advanced Solid Tumors",[89],"2026-08-26T02:19:16.454910Z","2026-05-05T02:35:31.918767Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT05941507","A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors",[89],"2026-08-26T02:17:01.714035Z","2026-04-29T02:57:57.104368Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT05396612","Role of the Immune Environment in Response to Therapy in Breast Cancer",[],"2026-08-26T02:16:22.235886Z","2026-05-13T02:55:06.349680Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT05037825","The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors",[],"2026-08-26T02:16:03.788292Z","2026-05-13T02:55:06.279892Z",{"nct_id":188,"title":189,"phases":190,"status":191,"updated_at":192,"content_modified":193},"NCT07015853","ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation",[20],"NOT_YET_RECRUITING","2026-08-26T02:18:58.958025Z","2026-05-05T02:43:29.674603Z",{"nct_id":195,"title":196,"phases":197,"status":191,"updated_at":198,"content_modified":199},"NCT07552181","Trial of Pembrolizumab\u002FChemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer",[20],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:27.670496Z",{"nct_id":201,"title":202,"phases":203,"status":191,"updated_at":204,"content_modified":205},"NCT07723469","Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery",[12],"2026-08-26T02:18:05.435729Z","2026-07-24T01:27:14.923064Z",{"nct_id":207,"title":208,"phases":209,"status":210,"updated_at":211,"content_modified":212},"NCT05848739","A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors",[64],"ACTIVE_NOT_RECRUITING","2026-08-03T03:25:11.951163Z","2026-05-05T02:43:29.390383Z",{"nct_id":214,"title":215,"phases":216,"status":210,"updated_at":217,"content_modified":218},"NCT05933265","Study of LP-184 in Patients With Advanced Solid Tumors",[89],"2026-08-03T02:32:04.757108Z","2026-05-05T02:43:28.624294Z",{"nct_id":220,"title":221,"phases":222,"status":210,"updated_at":223,"content_modified":224},"NCT05783622","Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies",[64],"2026-08-03T02:50:47.306763Z","2026-05-05T02:43:27.423256Z",[226],{"biomarker":227,"count":228,"slug":229},"Programmed Cell Death 1 Ligand 1",4,"programmed-cell-death-1-ligand-1",[231,235,238,241,245,248,252,256,259,263,266,269,273,276,279,282,285,289,292,295,299,302,305,308],{"state":232,"count":233,"slug":234},"California",17,"california",{"state":236,"count":233,"slug":237},"New York","new-york",{"state":239,"count":233,"slug":240},"Texas","texas",{"state":242,"count":243,"slug":244},"Florida",12,"florida",{"state":246,"count":243,"slug":247},"Georgia","georgia",{"state":249,"count":250,"slug":251},"Michigan",11,"michigan",{"state":253,"count":254,"slug":255},"Massachusetts",10,"massachusetts",{"state":257,"count":254,"slug":258},"Tennessee","tennessee",{"state":260,"count":261,"slug":262},"Ohio",9,"ohio",{"state":264,"count":261,"slug":265},"Pennsylvania","pennsylvania",{"state":267,"count":261,"slug":268},"Virginia","virginia",{"state":270,"count":271,"slug":272},"Colorado",7,"colorado",{"state":274,"count":271,"slug":275},"Connecticut","connecticut",{"state":277,"count":271,"slug":278},"Illinois","illinois",{"state":280,"count":271,"slug":281},"Maryland","maryland",{"state":283,"count":271,"slug":284},"Missouri","missouri",{"state":286,"count":287,"slug":288},"Arizona",6,"arizona",{"state":290,"count":287,"slug":291},"Minnesota","minnesota",{"state":293,"count":287,"slug":294},"North Carolina","north-carolina",{"state":296,"count":297,"slug":298},"Kentucky",5,"kentucky",{"state":300,"count":297,"slug":301},"Oregon","oregon",{"state":303,"count":297,"slug":304},"Washington","washington",{"state":306,"count":228,"slug":307},"Alabama","alabama",{"state":309,"count":228,"slug":310},"Arkansas","arkansas"]